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Summary Formalin-fixed paraffin-embedded material from 57 patients in whom curative resection of pancreatic carcinoma had been
attempted was analysed by an immunohistochemical procedure to estimate proliferation and p53 protein expression. Using the monoclonal
antibody (MAb) MIB-1, which recognizes a Ki-67 epitope, the proliferating cell index (PCI, percentage of immunoreactive tumour nuclei) and
proliferating cell area (PCA, percentage of immunoreactive tumour nuclear area) were calculated using an interactive image analysis system
and were compared with semiquantitative scoring of stainability. MAb DO-7, which recognizes both wild- and mutant-type p53 protein, was
used to assess p53 expression in the same material. MIB-1 stainings were of high quality in 53 tumours. The median PCI was 29.7% (range
0.5-82.1%) and the median PCA was 10.6% (range 0.0-36.5%). There was a close correlation between PCI and PCA (P< 0.0001). PCI and
PCA values were in conformity with the semiquantitative scoring (P < 0.0001). The p53 immunohistochemical stainings were successful in
48 tumours and the protein was expressed in 22 (46%). High PCI values (> 45%, n = 14) correlated with shorter survival time (P< 0.01). PCA
(P< 0.05) and the expression of p53 protein (P< 0.001) were independent prognostic variables.
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Different epitopes ofthe Ki-67 antigen (Ki-67, Ki-S1, Ki-S5, MIB-
1-3) have been used to estimate proliferation in various tumours
(Kelleher et al, 1994). The proliferating rate has often been
described as a proliferating cell index (PCI) (Pinder et al, 1995) or
has been scored subjectively (Railo et al, 1993; Lam et al, 1996).
The PCI may be calculated with or without the use of interactive
image analysis systems (Pinder et al, 1995; Lam et al, 1996).
The more recently developed MIB antibodies exhibit a pattern
of immunostaining in formalin-fixed paraffin-embedded material
identical with that of Ki-67 antibodies in fresh or frozen material
(McCormick et al, 1993) and correlate with other markers of
proliferation (Weidner et al, 1994). Thus, expression of the Ki-67
antigen has been used in studies on archival tumour material and
has been correlated with patient survival time (Railo et al, 1993;
Pinder et al, 1995).
p53 alterations may be detected at the protein level by immuno-
histochemical staining procedures (IHC) and at the DNA or RNA
level by direct sequence studies (Bodner et al, 1992; Berrozpe et
al, 1994). The presence of p53 abnormalities correlates in some
tumours with short survival time (Isola et al, 1992; Martin et al,
1992; Hamelin et al, 1994). Only a few studies have been
published on the prognostic value of p53 alterations in pancreatic
carcinoma, and the results are contradictory (DiGiuseppe et al,
1994; Lundin et al, 1996).
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We assessed the proliferating activity in pancreatic carcinoma
using IHC on formalin-fixed paraffin-embedded material using the
MIB-1 antibody. PCI and the proliferating cell area (PCA) were
calculated using interactive image analyses and compared with
scoring. Immunostaining with the DO-7 antibody was performed
to detect p53 alterations. The prognostic significance ofPCI, PCA
and p53 protein expression was analysed.
MATERIALS AND METHODS
Patient and tumour material
Tumour tissue was available from 57 patients with pancreatic
carcinoma in whom curative pancreaticoduodenal resection had
been attempted in the Department of Surgery, Stockholm Soder
Hospital, between 1981 and 1992. It was not possible to evaluate
MIB-1 IHC in four tumours. Thus, the series comprised 53
patients, 17 men with a median age of 65 years (range 45-83
years) and 36 women with a median age of66 years (range 45-83
years). In 48 patients, staining of the tumours with the DO-7 anti-
body was ofhigh quality. Complete clinical records were available
in all cases. The female dominance is explained by the sex distrib-
ution ofelderly people in the catchment area ofthe hospital.
There were five long-term survivors. Four patients are still alive
after 48, 60, 64 and 126 months. One patient died after 80 months
without a recurrence. Fourpatients died in the perioperative period
and were censored in the survival analyses.
All tumours were located in the head of the pancreas. Tumour
stage was assessed according to the post-surgical TNM system,
and tumourdifferentiation and malignancy grading were estimated
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(Hermanek and Sobin, 1987, pp 65-87). All original haema-
toxylin-eosin (H and E)-stained slides were re-examined and
confirmed the diagnosis ofductal pancreatic carcinoma.
The IHC procedure
The avidin-biotin-peroxidase complex (ABC) technique was
used. Sections (4 gm thick) were cut from the routinely processed
formalin-fixed paraffin-embedded blocks and mounted on
Superfrost glass slides. One section was H and E-stained and the
histopathological diagnosis was verified. They were deparaffin-
ized in xylene and rehydrated to distilled water through the
conventional ethanol scale. To enhance immunoreactivity, the
sections were microwave heated. The slides were immersed
in 0.01 M sodium citrate buffer (pH 6.0), placed into plastic
containers and incubated in a conventional domestic microwave
oven, equipped with a rotation plate, at its maximal power until
boiling. Then, at 70% of its maximal power, in three consecutive
intervals of 5 min each, the buffer was replenished after each
interval. After microwave irradiation, the sections were cooled
down to room temperature for about 20 min. Subsequently, the
slides were rinsed in distilled water and incubated with 0.6%
hydrogen peroxide for 25 min and rinsed in distilled water.
Thereafter, they were immersed in 1% bovine serum albumin
(BSA) for 30 min and incubated overnight at 40C with the primary
monoclonal antibodies (MAbs). MIB-1 MAb (code no. 0505,
Immunotech, Marseilles, France), recognizing an epitope of the
Ki-67 antigen, was diluted 1:150 in 1% BSA in buffer and the DO-
7 MAb (Dako, Glostrup, Denmark) reacting with both wild-type
and mutant p53 protein in 1:50. The slides were rinsed in buffer
and incubated with biotinylated horse anti-mouse antibody, diluted
1:200 in buffer, for 30 min. The buffer used was a mixture of
phosphate-buffered saline (0.01 M) and Tris-buffer (0.05 M), in
saline (0.15 M), pH 7.6. The sections were incubated with the
avidin-biotin-peroxidase complex (Vectastain-ABC Kit, Vector
Lab, Burlingam, CA, USA) for 30 min. They were rinsed in
buffer and developed in 3-amino-9-ethyl-carbazol (AEC) (Sigma
Chemicals, St Louis, MO, USA). The nuclei were counterstained
with Meyer's haematoxylin. The slides were mounted with gly-
cerol gelatine (Merck, Darmstadt, Germany). One slide with
breast carcinoma known to contain MIB-1 reactive cells or cells
showing p53 protein expression was included in each staining
procedure as a control forimmunoreactivity. One slide preparation
in which the primary antibody had been replaced by 1% BSA in
buffer was used as 'negative' control.
IHC evaluation
The MIB-1 immunoreactivity was evaluated by image analysis
using the ACAS ICM System (Ahrens Cytometry Systems,
Bargteheide, Germany) (Parrado et al, 1996). PCI (percentage of
positively stained tumour nuclei) and PCA (percentage of posi-
tively stained tumour nuclear area) were calculated. The
immunostaining analysis software module allowed automatic
detection and evaluation of immunoreactive and counterstained
nuclei. The system was equipped with a Leitz Orthoplan micro-
scope, plan objective 40/0.95, a single-chip colour CCD (charge-
coupled device) camera (JVC TK 870) and a colour-image frame
grabber. In the immunostaining analysis routine of the system,
'positive' reddish-brown AEC tumour nuclei were detected and
discriminated from 'negative' blue haematoxylin Meyer nuclei.
The measuring sequence consisted oftwo general phases: one cali-
bration phase and one measuring phase. During the calibration
phase, the immunostained nuclei were defined by the user with
respect to the colour shade of the positive staining (two or three
test image fields). During the measuring phase, the 'positive' and
'negative' nuclei were detected automatically but were corrected
interactively by adding or removing 'positive/negative' particles.
This technique allowed exclusion of stromal, vascular, necrotic,
haemorrhagic and other irrelevant areas, as well as the inclusion of
appropriate corrections for superimposed nuclei ('doublets'), for
multiple or giant nuclei and for too weakly stained nuclei.
Calculations were based on 25 fields in each section within
cancer cell areas. Fields were not selected at random to avoid areas
with stroma, but the measurements were not performed specifi-
cally in the most proliferative areas to obtain an average estima-
tion ofthe specimens.
The interactive measurement of MIB-1-stained nuclei was
compared with conventional semiquantitative scoring. The scoring
system was designed as follows: -, no staining; (+), clear staining
in less than 20% of the nuclei; +, clear staining in up to 40%; ++,
clear staining in up to 60%; and +++, more than 60% ofthe nuclei
clearly stained.
The p53 immunoreactivity was only scored conventionally. As
in the MIB-1 immunostainings, specimens with only occasional
(< 1%) weakly immunoreactive nuclei were scored as negative
(Scarpa et al, 1993). Negative cases were compared with those
with positive scoring (+, ++ or +++) in the survival analysis.
Statistics
The log-rank test was used to assess differences in survival time
between groups. Continuous factors were tested for influence on
survival using the Cox bivariate regression. Factors remaining
significant for survival in the bivariate analysis were tested in a
Cox multivariate regression analysis. When comparing the PCI
and PCA with conventional MIB-1 scoring and with p53 protein
expression Student's unpaired t-test was used. The PCI was
compared with PCA using simple regression analysis.
RESULTS
Tumour stage - histopathological grade
There were 27 stage I, eight stage II and 18 stage III tumours. The
median size was 25 mm (range 10-70 mm). There were five well-
differentiated, 18 moderately differentiated and 30 poorly differ-
entiated tumours.
MIB-1 immunoreactivity (Ki-67 antigen)
A median of 384 nuclei (range 163-557) were evaluated in the 53
specimens with MIB-l immunostainings (Figure 1). The median
PCI value was 29.7% (range 0.5-82.1%). There was no correlation
between PCI and tumour grade. According to scoring, there were
two specimens without immunoreactivity, 22 scored as (+), 14 as +
and 15 specimens as ++. Tumour specimens classified as -/(+) had
significantly lower PCI values (15.6 ± 11.3%, mean ± s.d.) than
those scored as +/++ (42.9 ± 18.1%, mean ± s.d.) (P < 0.0001).
Thus, there was good agreement between the two methods. The
median PCA was 10.6% (range 0.0-36.5%) and the PCAcorrelated
well with the PCI (P < 0.0001). Also, with respect to the PCA,
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Figure 1 Ki-67 immunoreactivity in pancreatic carcinoma using the MIB-1
MAb. Immunoreactive nuclei have a distinct reddish-brown colour in contrast
to the blue haematoxylin nuclei (horizontal bar = 50 ,im)
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Figure 2 p53 immunoreactivity in pancreatic carcinoma using the DO-7
MAb. Perineural invasion is seen. The colour is clearly reddish-brown in the
nuclei immunoreactive for p53 protein expression (horizontal bar = 50 gm)
tumours scored as -/(+) had lower values (7.1 ± 6.9%, mean ± s.d.)
than those scored as +/++ (18.7 ± 9.8%, mean ± s.d.) (P < 0.0001).
p53 immunoreactivity (DO-7)
Evaluation ofthe p53 stainings was possible in 48 cases (Figure 2).
There were 22 tumour specimens (46%) that were immunoreactive
Survival time (months)
Figure 3 Patient survival time in relation to proliferating cell area (PCA) and
proliferating cell index (PCI) in pancreatic carcinoma (n = 53). Proliferating
cell area (PCA) values above the median were associated with shorter
survival (P < 0.01) (A). Patients with low PCI values (< 45%) had longer
survival time than those with PCI > 45% (P < 0.05) (B)
for p53 protein expression. Three specimens were classified as +,
13 as ++ and six as +++. No p53 protein expression was found in
22 tumours and, in four stained nuclei, was found only occasionally
(<1%). Thus, 26 tumours (54%) were classified as p53 negative.
Survival analysis
There was a relation between tumour size (P < 0.01) and survival
time, but tumour stage and tumour grade had no influence on the
prognosis. The median overall survival time was 13 months.
Patients with PCA values below the median (10.6%) had a
better prognosis than patients with values above the median
(P < 0.01) (Figure 3A), whereas patients with tumours with a PCI
below the median (29.7%) did not survive longer than those with a
PCI above the median. However, if a higher PCI level was chosen
as cut-off when comparing survival time, patients with PCI values
< 45% (n = 14) had a longer survival time than those with PCI
values > 45% (n = 39) (P < 0.01) (Figure 3B). Correspondingly,
patients with tumours scored as -I(+) (n = 24) survived longer than
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Table 1 Factors influencing survival time in 53 patients resected for
pancreatic carcinoma determined by Cox bivariate regression analysis with
respect to disease-specific survival
Factor RH Cl P
Age (years)a 1.15 0.83-1.60 0.395
Sex (female vs male) (0/1) 1.49 0.80-2.76 0.202
Size (mm)a 1.67 1.21-2.31 0.002
Stage (I vs 11 or 111) (0/1) 1.65 0.90-3.03 0.102
Grade (well vs moderate or poor) (0/1) 2.24 0.68-7.30 0.172
PCI (< 45% vs > 45%) (0/1) 2.18 1.11-4.30 0.021
PCA (< median vs > median) (0/1) 2.24 1.21-4.13 0.009
MIB-1 score (- or (+) vs + or ++) (0/1) 1.79 0.97-3.28 0.058
p53 (negative vs positive) (0/1) 2.71 1.41-5.19 0.002
aContinuous, per 10-unit increments. 0/1 represents coding for the two
patient groups; underlined groups represent a longer survival time. PCI,
proliferating cell index; PCA, proliferating cell area. p53 (48 events). RH,
relative hazards; Cl, 95% confidence intervals.
Table 2 Evaluation of prognostic factors in 53 patients resected for
pancreatic carcinoma by Cox multivariate regression analysis with respect to
disease-specific survival
Factor RH Cl P
p53 (negative vs positive) (0/1) 3.26 1.65-6.45 < 0.001
Sex (female vs male) (0/1) 2.45 1.21-4.96 0.013
PCA (< median vs > median) (0/1) 2.08 1.08-3.99 0.028
0/1 represents coding for the two patient groups; underlined groups
represent a longer survival time. PCA, proliferating cell area; RH, relative
hazards; Cl, 95% confidence intervals. p53 (48 events).
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Figure 4 Patient survival time in relation to p53 protein expression (n = 48).
Survival time was shorter for patients with tumours immunoreactive for the
p53 protein (P< 0.01)
those with +/++ tumours (P = 0.05). The prognostic variables
tested in the bivariate analysis are shown in Table 1. The PCA was
a stronger predictor of survival than the PCI and had an indepen-
dent prognostic value (P < 0.01) (Table 2).
Patients classified as negative for p53 protein expression
(n = 26) had longer survival time than those with positive p53
scores (n = 22) (P < 0.01) (Figure4). Positive p53 immunostaining
Table 3 Patient survival time - distribution according to prognostic variables
Prognostic variable Median survival time (months)
PCI <45% 16.0
PCI > 45% 8.0
PCI < median value 18.0
PCA> median value 8.0
MIB-1 scoring (-/(+)) 16.5
MIB-1 scoring (+/++) 8.0
p53 negative 16.0
p53 positive 8.7
Female 14.5
Male 9.0
PCI, proliferating cell index; PCA, proliferating cell area. p53 (48 events).
was the most pronounced independent prognosticator of short
survival time (P < 0.001) (Table 2). The median survival time in
relation to prognostic variables is shown in Table 3.
The PCI was not higher in tumours with p53 protein expression
(29.5 ± 21.5%, mean ± s.d.) than in those negative for the protein
(29.8 ± 19.7%, mean + s.d.).
Tumour characteristics in the five long-term survivors, ofwhom
four were women, are shown in Table 4. All five long-term
survivors had stage I tumours of 30 mm or less in size and were
classified as p53 negative, but the MIB-1 pattern was varying.
DISCUSSION
Immunohistochemical staining with the MIB-1 antibody has been
performed in various tumours but not in pancreatic neoplasms
(Pinder et al, 1995; Lam et al, 1996; Parrado et al, 1996). The
present study shows that the MIB-1 antibody is also highly
effective in archival material from pancreatic carcinoma.
The proliferating activity of the tumour cells was evaluated by
interactive image analysis and expressed as PCI and PCA. While
PCI is frequently used to estimate the proliferating rate (Lam et al,
1996; Parrado et al, 1996), estimation of PCA has been used less
often (Pinder et al, 1995; Parrado et al, 1996). Lundin et al (1995)
used polyclonal Ki-67 antibodies in pancreatic carcinoma and
found a median PCI value (26%) similar to that in the present
series. In comparison to image analysis, semiquantitative scoring
is less complicated. In the present study, the two techniques were
compared and estimation ofthe proliferating activity seemed to be
in accordance. Using image analysis, the PCA may also be calcu-
lated and there was a close correlation between PCI and PCA.
In the present series, only PCI levels exceeding 45% were
related to short survival time. This is in agreement with Lundin et
al (1995) who found that Ki-67 labelling exceeding 50% of the
nuclei was associated with a poor outcome. Interestingly, we
found that the PCA was an independent and stronger prognosti-
cator than PCI. In comparison, studies ofmorphometric variables
in pancreatic carcinoma have demonstrated that the area and
variation in the area of tumour cells have a prognostic value in
pancreatic carcinoma (Linder et al, 1995).
Paraffin sections, frozen material and carcinoma cell lines
have been investigated for p53 abnormalities in pancreatic carci-
noma (Barton et al, 1991; Ruggeri et al, 1992; Berrozpe et al,
1994). IHC has shown the same p53 protein pattern in frozen
sections as in paraffin ones inpancreatic carcinoma (van dem Berg
et al, 1993). Although there are sources of error in determination
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Table 4 Pattern of prognostic variables in five long-term survivors (48-126 months) resected for pancreatic carcinoma
Case Tumour stage Tumour grade Tumour size (mm) PCI (%) PCA (%) p53 classification Sex
1 Well 30 9.8 4.1 Negative Female
2 Poor 24 0.5 0.0 Negative Male
3 Well 23 15.7 6.5 Negative Female
4 Moderate 11 33.0 8.9 Negative Female
5 Moderate 20 82.0 36.0 Negative Female
PCI, proliferating cell index; PCA, proliferating cell area.
of p53-alterations, there is in general a correspondence between
IHC results and the findings obtained using molecular biological
techniques (Barton et al, 1991; Ruggeri et al, 1992; Kalthoff et al,
1993). The percentage of tumours with p53 alterations in the
present study is within the range described in the literature
(20-75%), as estimated by IHC (Barton et al, 1991; van den Berg
et al, 1993) or molecular biological techniques (Kalthoff et al,
1993; Scarpa et al, 1993; Pellegata et al, 1994). p53 immunoreac-
tive cells have also been detected in peritumoral inflamed tissue
specimens (Kalthoff et al, 1993). This phenomenon was not
observed in the present study nor in the series ofDiGuiseppe et al
(1994). Extreme antigen enhancement in IHC using the DO-7
MAb has been shown to yield immunoreactivity in normal cells,
stromal cells and in tumour cells with p53 gene abnormalities
precluding expression of the protein (Baas et al, 1996). In the
present series, however, there was only immunoreactivity in
tumour nuclei.
Although there are some studies ofp53 alterations in pancreatic
carcinoma, only a few discuss the impact on survival (DiGuiseppe
et al, 1994; Lundin et al, 1996). As in the present study, the IHC
technique was used. In the series ofDiGuiseppe et al (1994), 26 of
48 tumours were immunoreactive and the difference in survival
time between 'p53-positive' and 'p53-negative' patients (10
months and 20 months respectively) reached borderline signifi-
cance. Lundin et al (1996) also used the DO-7 antibody but found
no relation to survival, however patients with tumours expressing
less than 20% ofp53 immunoreactive nuclei were compared with
those with 20% or more in the survival analyses. In the present
study with a different cut-off level (1%), immunoreactivity for the
p53 protein was the strongest independent prognosticator.
In the present study, MIB-1, PCI or PCA was not increased in
p53 immunoreactive tumours. Similar findings have been made
in lung carcinoma (M0rkve et al, 1992). In comparison, in one
immunohistochemical study ofpancreatic carcinoma, the prolifer-
ating index (percentage of cells > GI Go) was not associated with
p53 immunoreactivity (DiGuiseppe et al, 1994). It has been
suggested that Ki-67 is not involved in the same steps of cell
proliferation as p53, and therefore a similar staining pattern could
not be expected (Thompson et al, 1992).
In conclusion, immunohistochemical staining by the MIB-1
antibody is feasible in paraffin sections of pancreatic carcinoma.
The pattern of expression is clear and is possible to evaluate by
conventional scoring. Alternatively, it is possible to calculate the
PCI and PCA using an interactive image analysis system. In the
majority of tumours, expression of p53 protein can be evaluated
using the immunohistochemical technique. Although the number
of patients in the present series is limited, highly proliferative
pancreatic tumours or those expressing the p53 protein were asso-
ciated with shorter survival time.
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